



Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

August 31, 2026

BOSTON--(BUSINESS WIRE)--Aug. 31, 2026-- [Seaport Therapeutics, Inc.](#) (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences:

- **21st Annual Wells Fargo Healthcare Conference**
 - September 8–10, 2026
 - Seaport will participate in one-on-one investor meetings
- **Citi's 2026 Biopharma Back to School Conference**
 - September 9–10, 2026
 - Fireside chat: September 9, 2026 at 1:00 p.m. ET
 - Seaport will participate in one-on-one investor meetings

A live webcast of the Citi fireside chat will be available on the Investors section of the Company's website at <https://investors.seaporttx.com/news-events/events>. An archived replay will be available following the presentation.

About Seaport Therapeutics

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph™ platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260831442211/en/>

Seaport Therapeutics

Media Contact:

Shannon Costello
Vice President, Communications
publicrelations@seaporttx.com

Investor Contact:

Adam Bero, Ph.D.
Head of Investor Relations
ir@seaporttx.com

Source: Seaport Therapeutics, Inc.